Metabolic syndrome prevalence in women with gestational
diabetes mellitus

k 2022

Metabolic syndrome prevalence in women with gestational diabetes mellitus

BARTÁKOVÁ, Vendula, Katarína CHALÁSOVÁ, Lukáš PÁCAL, Petr JANKŮ, Kateřina KAŇKOVÁ et. al.

Basic information

Original name

Metabolic syndrome prevalence in women with gestational diabetes mellitus

Authors

BARTÁKOVÁ, Vendula (203 Czech Republic, guarantor, belonging to the institution), Katarína CHALÁSOVÁ (703 Slovakia, belonging to the institution), Lukáš PÁCAL (203 Czech Republic, belonging to the institution), Petr JANKŮ (203 Czech Republic, belonging to the institution) and Kateřina KAŇKOVÁ (203 Czech Republic, belonging to the institution)

Edition

54rd annual DPSG Meeting Madrid, 2022

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

30202 Endocrinology and metabolism

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

RIV identification code

RIV/00216224:14110/22:00126684

Organization unit

Faculty of Medicine

Keywords (in Czech)

diabetes; těhotenství; metabolický syndrom

Keywords in English

diabetes; pregnancy; metabolic syndrome

Abstract

V originále

Background and aims: Gestational diabetes mellitus (GDM) is one of the most common complications in pregnancy. Women with GDM have a higher occurrence of peripartal complication as well as an increased risk of type 2 diabetes mellitus, metabolic syndrome (MS) and subsequent cardiovascular diseases after delivery or anytime later. However, MS could precede gravidity and GDM could represent manifestation of one of its components. The aims of the study were (i) to detect the prevalence of MS in women in the time of GDM diagnosis, (ii) to detect the prevalence of MS in the sub-group of GDM patients with any form of impaired glucose tolerance after delivery, and (iii) to find whether GDM women with MS have a higher risk of peripartal adverse. Materials and Methods: Study comprised n=455 women with GDM enrolled during 2013-2019. Following GDM diagnosis, subjects were followed in Diabetology centre in Faculty Hospital Brno, 65% (n=295) of them delivered in Faculty Hospital Brno and data on delivery were thus retrievable. 48% (n=219) GDM patients underwent repeated oGTT test up to 1 year after delivery with 11,4% (n=25) manifesting persistence or early conversion of GDM to permanent glucose intolerance (diabetes or prediabetes, evaluated according to WHO criteria). GDM was diagnosed according to IADPSG criteria. IDF criteria for MS definition were modified to pregnancy situation as a presence of a minimum of 3 of 5 criteria: GDM, BMI before pregnancy ≥30 kg/m2, blood pressure >130/85mmHg, triacyl-glyceroles (TAG) >1,7mmol/l, high density lipoproteins (HDL) <1,3mmol/l (with exception of BMI all parameters were evaluated in the second trimester of pregnancy). Following perinatal data were analysed: offspring weight (macrosomia), length of delivery, necessity of delivery induction or instrumental delivery, unplanned Caesarean section, Apgar score value. Results: Fully developed MS was detected in 22,6% (n=103) of GDM patients at 24th-28th week of pregnancy. In those with any form of persistent glucose intolerance after delivery the prevalence of MS was as high as 40%. Presence of MS in GDM patients was statistically significantly associated with two peripartal outcomes: higher incidence of pathologic Apgar score and macrosomia (P=0.01 resp. P= 0.0004, chi-square test). Conclusion: Presence of MS in GDM patients is a statistically significant risk factor (P= 0.04 chi-square test) for persistence of impaired glucose tolerance after delivery and selected adverse peripartal outcomes.

Links

LX22NPO5104, research and development project

Name: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění (Acronym: CarDia)

Investor: Ministry of Education, Youth and Sports of the CR, 5.1 EXCELES

Citovat

BARTÁKOVÁ, Vendula, Katarína CHALÁSOVÁ, Lukáš PÁCAL, Petr JANKŮ and Kateřina KAŇKOVÁ. Metabolic syndrome prevalence in women with gestational diabetes mellitus. In 54rd annual DPSG Meeting Madrid. 2022.

@proceedings{2218026,
   author = {Bartáková, Vendula and Chalásová, Katarína and Pácal, Lukáš and Janků, Petr and Kaňková, Kateřina},
   booktitle = {54rd annual DPSG Meeting Madrid},
   keywords = {diabetes; pregnancy; metabolic syndrome},
   language = {eng},
   title = {Metabolic syndrome prevalence in women with gestational diabetes mellitus},
   url = {http://dpsghome.org},
   year = {2022}
}

TY  - CONF
ID  - 2218026
AU  - Bartáková, Vendula - Chalásová, Katarína - Pácal, Lukáš - Janků, Petr - Kaňková, Kateřina
PY  - 2022
TI  - Metabolic syndrome prevalence in women with gestational diabetes mellitus
KW  - diabetes
KW  - pregnancy
KW  - metabolic syndrome
UR  - http://dpsghome.org
N2  - Background and aims: Gestational diabetes mellitus (GDM) is one of the most common complications in pregnancy. Women with GDM have a higher occurrence of peripartal complication as well as an increased risk of type 2 diabetes mellitus, metabolic syndrome (MS) and subsequent cardiovascular diseases after delivery or anytime later. However, MS could precede gravidity and GDM could represent manifestation of one of its components. The aims of the study were (i) to detect the prevalence of MS in women in the time of GDM diagnosis, (ii) to detect the prevalence of MS in the sub-group of GDM patients with any form of impaired glucose tolerance after delivery, and (iii) to find whether GDM women with MS have a higher risk of peripartal adverse. Materials and Methods: Study comprised n=455 women with GDM enrolled during 2013-2019. Following GDM diagnosis, subjects were followed in Diabetology centre in Faculty Hospital Brno, 65% (n=295) of them delivered in Faculty Hospital Brno and data on delivery were thus retrievable. 48% (n=219) GDM patients underwent repeated oGTT test up to 1 year after delivery with 11,4% (n=25) manifesting persistence or early conversion of GDM to permanent glucose intolerance (diabetes or prediabetes, evaluated according to WHO criteria). GDM was diagnosed according to IADPSG criteria. IDF criteria for MS definition were modified to pregnancy situation as a presence of a minimum of 3 of 5 criteria: GDM, BMI before pregnancy ≥30 kg/m2, blood pressure >130/85mmHg, triacyl-glyceroles (TAG) >1,7mmol/l, high density lipoproteins (HDL) <1,3mmol/l (with exception of BMI all parameters were evaluated in the second trimester of pregnancy). Following perinatal data were analysed: offspring weight (macrosomia), length of delivery, necessity of delivery induction or instrumental delivery, unplanned Caesarean section, Apgar score value. Results: Fully developed MS was detected in 22,6% (n=103) of GDM patients at 24th-28th week of pregnancy. In those with any form of persistent glucose intolerance after delivery the prevalence of MS was as high as 40%. Presence of MS in GDM patients was statistically significantly associated with two peripartal outcomes: higher incidence of pathologic Apgar score and macrosomia (P=0.01 resp. P= 0.0004, chi-square test). Conclusion: Presence of MS in GDM patients is a statistically significant risk factor (P= 0.04 chi-square test) for persistence of impaired glucose tolerance after delivery and selected adverse peripartal outcomes.
ER  -

BARTÁKOVÁ, Vendula, Katarína CHALÁSOVÁ, Lukáš PÁCAL, Petr JANKŮ and Kateřina KAŇKOVÁ. Metabolic syndrome prevalence in women with gestational diabetes mellitus. In \textit{54rd annual DPSG Meeting Madrid}. 2022.

Detailed Information on Publication Record